Evidence map›Paper›PMID 36520793›Full record

ArticlePloS one2022

Engineering a "detect and destroy" skin probiotic to combat methicillin-resistant Staphylococcus aureus.

Changhui Guan, Peter J Larson, Elizabeth Fleming, Alexander P Tikhonov, Sara Mootien, Trudy H Grossman, Caroline Golino, Julia Oh

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. EngineeredBiochemistry · 2026
    Article
  3. Probiotic-Based Materials as Living Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Feasibility of engineeredBioengineering & translational medicine · 2024
    Article
  10. Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Changhui GuanThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Peter J LarsonThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.ORCID 0000-0002-2806-284X
Elizabeth FlemingThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.
Alexander P TikhonovAzitra, Inc., Branford, Connecticut, United States of America.ORCID 0000-0003-3808-9701
Sara MootienAzitra, Inc., Branford, Connecticut, United States of America.
Trudy H GrossmanAzitra, Inc., Branford, Connecticut, United States of America.
Caroline GolinoUCONN Health (University of Connecticut), Farmington, Connecticut, United States of America.
Julia OhThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.ORCID 0000-0002-5534-7023
Jackson Laboratory · USUConn Health · US

Funding

Metagenomes to Therapeutics: Defining the Rules for Engineering the Skin MicrobiomeDP2GM126893 · NIGMS · JACKSON LABORATORY · PI OH, JULIA · 2017 to 2017
$2.8M
Skin Microbiome of Monogenic Skin DisordersR21AR075174 · NIAMS · JACKSON LABORATORY · PI OH, JULIA · 2019 to 2022
$466k
Community organizing: Harnessing the interactions of the microbiome as a basis for novel therapeutic strategiesK22AI119231 · NIAID · JACKSON LABORATORY · PI OH, JULIA · 2016 to 2017
$270k
NIAID NIH HHS K22 AI119231NIAMS NIH HHS R21 AR075174NIGMS NIH HHS DP2 GM126893
6 · The paper itself

Abstract

The prevalence and virulence of pathogens such as methicillin-resistant Staphylococcus (S.) aureus (MRSA), which can cause recurrent skin infections, are of significant clinical concern. Prolonged antibiotic exposure to treat or decolonize S. aureus contributes to development of antibiotic resistance, as well as depletion of the microbiome, and its numerous beneficial functions. We hypothesized an engineered skin probiotic with the ability to selectively deliver antimicrobials only in the presence of the target organism could provide local bioremediation of pathogen colonization. We constructed a biosensing S. epidermidis capable of detecting the presence of S. aureus quorum sensing autoinducer peptide and producing lysostaphin in response. Here, we demonstrate in vitro activity of this biosensor and present and discuss challenges to deployment of this and other engineered topical skin probiotics.

Indexed as

Methicillin-Resistant Staphylococcus aureusProbioticsStaphylococcal InfectionsAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsStaphylococcus aureusVirulenceAnti-Bacterial Agents

Identifiers

PMID36520793
PMCPMC9754240
OpenAlexW4311557061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.